The Endocannabinoid System Explained: The Regulatory System Most People Were Never Taught About
You've heard of the nervous system. The immune system. The digestive system.
There's another biological signaling system — formally described only in the last few decades — that somehow still doesn't come up very often in everyday health conversations.
It's called the endocannabinoid system. And this article is going to explain it without turning it into a cannabis article, without overselling what the science says, and without asking you to buy anything.
That's a different kind of wellness article. Good. You're in the right place.
This is Article #3 in the TrueMedX cornerstone series. Article #1: Your Body Doesn't Work in Pieces Article #2: Food First. Supplements Second.
If you arrived here first — those two are worth reading. They built the foundation this article stands on.
Table of contents
Summary
The Endocannabinoid System (ECS) is a biological signaling system found in mammals — involved in a wide range of physiological processes — that doesn't come up nearly as often in everyday health conversations as it probably should
It is not a cannabis system; the body produces its own endocannabinoid signaling molecules entirely independent of cannabis
The ECS has three core components: endocannabinoids (lipid-derived signaling molecules the body makes on demand), receptors (distributed broadly throughout the body), and enzymes (which help end the signal after it has served its purpose)
Both major endocannabinoids — anandamide and 2-AG — contain arachidonic acid in their molecular structure and arise from arachidonic-acid-containing membrane lipids; the dietary fatty-acid environment is therefore part of the biological context in which ECS signaling occurs
Chip Paul holds U.S. Patent No. 10,646,535, which describes methods for modulating the ECS using non-cannabis, plant-based agents — reflecting years of research into this system before most wellness conversations were even having it
This is Article #3 in the TrueMedX cornerstone series: The System → The Raw Materials → The Regulation
Your body uses signals to maintain balance. The ECS is part of that story.
Your body is constantly exchanging information across cells, tissues, and systems. That communication is part of how biology responds to changing conditions and maintains internal stability.
Hormones are signals. Neurotransmitters are signals. And there are other signaling systems most of us were never taught much about.
The ECS is one of them.
In Article #2, we established that essential fatty acids are nutritional raw materials connected to biological signaling. Here's the signaling system we were pointing toward.
The endocannabinoid system explained — without making it a cannabis conversation
Let's get the obvious thing out of the way first, because the name creates confusion and it's worth addressing directly.
The endocannabinoid system sounds like it has something to do with cannabis. And in the history of how it was discovered, there is a connection — but not in the way most people assume.
Where the name comes from — and why it misleads people
The scientific components of the ECS were identified through a sequence of discoveries beginning in the late 1980s. Researchers studying how certain plant-derived compounds interact with the human body identified specific receptors. They found that the body had binding sites — specific molecular docking points — that these compounds were fitting into.
That raised an obvious question: why would the body have receptors for a compound found in a plant? The answer turned out to be that the body wasn't waiting for the plant. It had been making its own signaling molecules for those receptors all along. The plant-derived compound had simply provided the scientific thread that led researchers to a system the body had been using independently.
CB1 — the first cannabinoid receptor to be molecularly cloned — was characterized in 1990 by Matsuda and colleagues. In 1992, Devane and colleagues identified the first endogenous signaling molecule that binds to it: arachidonyl ethanolamide, named anandamide. In 1995, Mechoulam and colleagues, and separately Sugiura and colleagues, identified 2-arachidonoylglycerol — 2-AG. The recognition of these components as a coherent system developed across that decade of research, not at a single moment and not through the work of any single laboratory.
It was discovered through the science. The system itself predates that discovery by a very long time.
The ECS is not something researchers invented or proposed. It is something they found — already present, already operating, in mammalian biology. Identifying a system and describing its components is not the same as creating it. The discovery happened in the late 20th century. The system has been part of mammalian biology for far longer than that.
Which means the conversation about the endocannabinoid system is a biology conversation. Not a cannabis conversation.
Three parts. One signaling system.
The endocannabinoid system has three core components. Understanding all three matters — because the system only makes sense when you see how they work together.
1. Endocannabinoids: signaling molecules made on demand
Anandamide and 2-arachidonoylglycerol (2-AG) are the two most well-studied endocannabinoids. They are lipid-derived signaling molecules — built from fatty acids present in cell membrane phospholipids — and they are produced on demand in response to physiological signals rather than stored in advance and released when needed.
That distinction is worth sitting with. The body synthesizes these molecules when they are called for, uses them, and then breaks them down.
2. Receptors: distributed broadly throughout the body
CB1 and CB2 are the two most studied receptors in the endocannabinoid system. Both are G protein-coupled receptors — a class the body uses extensively for cellular communication.
CB1 is highly expressed in the brain and central nervous system and is also found in peripheral tissues including the gut, liver, and adipose tissue. CB2 was originally characterized as a peripheral receptor, with high expression in immune-associated tissues. Subsequent research has found broader CB2 distribution — including in the central nervous system — than that early characterization suggested.
The simplified shorthand — CB1 is the brain receptor, CB2 is the immune receptor — is the kind of reduction that makes things easier to say and less accurate to mean. Neither receptor is exclusively confined to one system or organ.
Enzymes: they help end the signal
Once an endocannabinoid has done its work, it needs to be broken down. Fatty acid amide hydrolase — FAAH — is the primary enzyme responsible for degrading anandamide. Monoacylglycerol lipase — MAGL — plays the same role for 2-AG. Both are part of how the body brings individual signaling events to a close.
Endocannabinoids carry signals. Receptors receive them. Enzymes help bring those signaling events to an end. Together, they're part of a much larger biological communication network.
A timing problem — not a hidden story
Here's where some wellness content goes sideways and starts implying conspiracy. We're not going to do that.
The education gap is a timeline issue
The molecular components of the ECS were described beginning in the late 1980s and through the 1990s. In scientific terms, that is genuinely recent. Research takes time to move from primary literature into clinical education — and longer still to reach general consumer health conversations.
That's not negligence. That's a timing issue inherent to how scientific knowledge moves through educational institutions and into everyday health discourse. What's observable is that the ECS remains less present in mainstream consumer health conversations than its scientific profile might suggest. That's the gap worth noting — and exactly why TrueMedX has been teaching this system for years.
Why TrueMedX thinks ECS literacy belongs in the health conversation
TrueMedX is not the first organization to teach the ECS. But it has been doing it consistently, and from a particular perspective: that understanding the biology comes before trying to support it. That the body's systems — including the ECS — are worth understanding on their own terms, not just as targets for products.
That orientation is part of what this cornerstone series is built around. Article #1 established that the body is interconnected. Article #2 established that foundational nutrition is part of that biological story. This article finishes the set by naming the signaling system those earlier conversations were pointing toward.
Hear Chip Explain It
The connection between dietary fatty acids and the Endocannabinoid System is one Chip has been teaching for years — and it's clearer when you hear him explain it directly. In this Chip Talks Health episode, Chip walks through how nutrition feeds the ECS and how omega-3 and omega-6 fatty acids relate to ECS signaling.
Want to go deeper into the research behind this? The ECS Education Academy companion article — How Nutrition Feeds the Endocannabinoid System: Omega-3, Omega-6, and ECS Balance — covers the underlying science in more detail.
The endocannabinoid system and nutrition — why the food conversation belongs here
In Article #2, we spent time on essential fatty acids — specifically on the argument that the dietary fatty-acid environment matters to biological function in ways that mainstream nutrition conversations tend to underemphasize.
This is where that argument connects to a specific piece of biology.
AEA and 2-AG contain arachidonic acid — and arachidonic acid is omega-6 derived
Both anandamide and 2-AG contain arachidonic acid in their molecular structure and arise from arachidonic-acid-containing lipids in cell membranes. Arachidonic acid belongs to the omega-6 fatty-acid family.
This is not a simple linear pipeline from dietary omega-6 to endocannabinoid. Fatty acid metabolism is more complex than that. But it does establish a meaningful biological relationship: the fatty acid composition of cell membranes — shaped in part by what we eat over time — is part of the biological environment in which endocannabinoid synthesis occurs.
Omega-6 isn't the bad guy. Biology isn't a Marvel movie.
The same omega-6 metabolic pathway that draws so much concern in modern nutrition discussions is also directly connected to endocannabinoid synthesis. The conversation around fatty acid balance is genuinely complex. Which is exactly why TrueMedX has been careful, for years, not to flatten it into a simple "cut your omega-6" message.
The dietary environment is part of the biological context
Omega-3 fatty acids — including EPA and DHA — contribute to the fatty acid composition of cell membranes. Research has examined how the availability of dietary fatty acids relates to endocannabinoid signaling, and the relationship is biologically interesting.
What that does not mean is that taking an omega-3 supplement straightforwardly improves or supports ECS function. The biology between membrane composition and endocannabinoid signaling is more nuanced than a supplement claim can capture, and we won't overstate it.
The precise and honest statement is this: what we eat helps shape the fatty-acid environment in which ECS signaling occurs. It's also part of why Chip Paul has spent so much time talking about omega-3 and omega-6 balance—including co-authoring a 2025 white paper on the U.S. food supply with renowned fatty-acid researcher Dr. Artemis Simopoulos. Get the white paper: Omega 3 & 6 Alarm with Dr. Artemis and Chip Paul
You can't intelligently talk about regulation without talking about nutrition. The biology insists on it.
Why Chip Paul has spent years studying the Endocannabinoid System — and what that work produced
If you've made it this far through the TrueMedX cornerstone series, you've probably noticed something: TrueMedX talks about the ECS differently than most supplement companies do. Less cannabis framing. More biology. More precision about what the research actually supports.
That reflects where the work started.
A research direction, documented
Chip Paul is the inventor of U.S. Patent No. 10,646,535 B1, granted May 12, 2020, which describes methods for modulating the Endocannabinoid System using non-cannabis, plant-based agents.
A patent documents protected intellectual property around a specific invention or method. It does not establish clinical outcomes — and we don't present it as though it does.
What the patent does reflect is a documented research direction: a serious inquiry into whether there were approaches to the ECS that didn't begin and end with cannabis — rooted in the biology of how the system actually works, conducted before ECS education was a mainstream wellness topic.
That question is what TrueMedX was built around.
What this means for the article you're reading
The ECS conversation does not begin and end with cannabis. Chip's patented work is part of the history behind why TrueMedX has been teaching that for years — through Chip Talks Health, through the TrueMedX Learning Center, through direct consultation at Neighborly Wellness.
We didn't start with a product and work backward to the biology. We started with the biology. That's a different approach, and it's the one that made sense to us.
The foundation, then the rest
Three articles. One connected idea.
Your body doesn't work in pieces.
Biology needs raw materials.
And those raw materials exist inside a world of signaling, communication, and regulation.
The System → The Raw Materials → The Regulation.
That's the foundation. And around here, foundation comes before complexity.
This is Article #3 in the TrueMedX cornerstone series. If you arrived here first, Article #1 is the right place to start.
FAQ
What is the Endocannabinoid System?
The Endocannabinoid System is a biological signaling system found in mammals, involved in a wide range of physiological processes. Its molecular components were formally identified beginning in the late 1980s and through the 1990s. The ECS has three core components: endocannabinoids (lipid-derived signaling molecules the body produces on demand), receptors (distributed broadly throughout the body), and enzymes (which help end the signal after it has served its purpose).
Is the ECS the same as the cannabis system?
No. The ECS is part of mammalian biology — the body produces its own endocannabinoid signaling molecules independent of cannabis. It was named through a research lineage that involved studying plant-derived compounds, but the system itself operates entirely within normal mammalian biology and does not require cannabis to function.
Why haven't I heard about this before?
The molecular components of the ECS were formally described beginning in the late 1980s — relatively recent in scientific terms. Research takes time to move into broader education and longer still into everyday health conversations. That's a timeline issue, not a hidden story.
What do the three parts of the ECS actually do?
Endocannabinoids — anandamide and 2-AG are the two most well-studied — are produced on demand and bind to receptors to initiate signaling. CB1 and CB2 are the two most studied receptors; both are found across many tissues, with different patterns of expression. Enzymes including FAAH and MAGL help end the signal by breaking down endocannabinoids after they've served their purpose.
What does the ECS have to do with nutrition?
Both major endocannabinoids — anandamide and 2-AG — contain arachidonic acid in their molecular structure and arise from arachidonic-acid-containing membrane lipids. Arachidonic acid belongs to the omega-6 fatty-acid family. The fatty-acid composition of cell membranes is shaped in part by what we eat, which makes the dietary environment part of the biological context in which endocannabinoid synthesis occurs. This is why TrueMedX treats foundational nutrition and ECS biology as part of the same conversation.
What is U.S. Patent No. 10,646,535?
It is a U.S. patent granted to inventor Chip Paul in May 2020, describing methods for modulating the Endocannabinoid System using non-cannabis, plant-based agents. A patent documents protected intellectual property around a specific method or invention. It does not establish clinical health outcomes.
Keep Reading
Chip Paul
Chip Paul is the co-founder of TrueMedX Bioceuticals and Neighborly Wellness and the inventor of U.S. Patent No. 10,646,535, which describes methods for modulating the Endocannabinoid System using non-cannabis, plant-based agents. He co-authored the 2025 white paper "Addressing the Omega-6 and Omega-3 Imbalance in the U.S. Food Supply" with Dr. Artemis P. Simopoulos. Chip teaches the biology behind TrueMedX's research through Chip Talks Health and believes the most useful thing a wellness company can do is explain the science before asking anyone to buy anything.
References / Further Reading
Primary scientific literature:
- Devane, W.A., et al. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34(5), 605–613.
- Matsuda, L.A., et al. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284), 561–564.
- Munro, S., Thomas, K.L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441), 61–65.
- Devane, W.A., et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.
- Mechoulam, R., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.
- Sugiura, T., et al. (1995). 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215(1), 89–97.
- Cravatt, B.F., et al. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384(6604), 83–87.
- Dinh, T.P., et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences, 99(16), 10819–10824.
- Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 4, 873–884.
- Atwood, B.K. & Mackie, K. (2010). CB2: a cannabinoid receptor with an identity crisis. British Journal of Pharmacology, 160(3), 467–479.
- Lafourcade, M., et al. (2011). Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nature Neuroscience, 14(3), 345–350.
- Simopoulos, A.P. (2002). The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomedicine & Pharmacotherapy, 56(8), 365–379.
Patent:
- Paul, C.W. (2020). U.S. Patent No. 10,646,535 B1. United States Patent and Trademark Office. Filed March 7, 2017. Granted May 12, 2020. Assignee: GnuPharma Corp. https://patents.google.com/patent/US10646535B1/en
Further education:
Leave a comment